Trevena to Report Fourth Quarter and Full Year 2018 Results on March 13, 2019
March 04, 2019 07:00 ET
|
Trevena Inc.
CHESTERBROOK, Pa., March 04, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ: TRVN), a biopharmaceutical company focused on the development and commercialization of new and innovative treatment...
Trevena to Present at the 21st Annual BIO CEO & Investor Conference
February 05, 2019 18:58 ET
|
Trevena Inc.
CHESTERBROOK, Pa., Feb. 05, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of new and innovative treatment options...
Trevena Announces $10 Million Registered Direct Offering of Common Stock
January 30, 2019 07:00 ET
|
Trevena Inc.
CHESTERBROOK, Pa., Jan. 30, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) (the “Company”) today announced that it entered into securities purchase agreements with two healthcare-focused...
Trevena Announces Receipt of Type A Meeting Minutes and Provides Regulatory Update for Oliceridine
January 28, 2019 07:00 ET
|
Trevena Inc.
– Company announces initial path forward on oliceridine NDA – – Company to host conference call on Monday, January 28 at 8:30 a.m. ET – CHESTERBROOK, Pa., Jan. 28, 2019 (GLOBE NEWSWIRE) --...
National Institute on Drug Abuse Presents Data on Trevena’s TRV734 at the 57th Annual Meeting of the American College of Neuropsychopharmacology
December 13, 2018 16:01 ET
|
Trevena Inc.
CHESTERBROOK, Pa., Dec. 13, 2018 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ: TRVN), a biopharmaceutical company focused on the development and commercialization of new and innovative treatment...
Trevena Promotes Robert T. Yoder to Senior Vice President and Chief Business Officer
December 10, 2018 07:00 ET
|
Trevena Inc.
CHESTERBROOK, Pa., Dec. 10, 2018 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ: TRVN), a biopharmaceutical company focused on the development and commercialization of new and innovative treatment...
Trevena Reports Third Quarter 2018 Financial Results and Announces Workforce Restructuring
November 08, 2018 07:00 ET
|
Trevena Inc.
– $70.0 Million of Cash, Cash Equivalents and Marketable Securities as of September 30, 2018 – – Company to host conference call and webcast at 8:00am EST – CHESTERBROOK, Pa., Nov. 08, 2018 (GLOBE...
Trevena Receives Complete Response Letter for Oliceridine from FDA
November 02, 2018 13:42 ET
|
Trevena Inc.
Company to host conference call and webcast on November 5th CHESTERBROOK, Pa., Nov. 02, 2018 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ: TRVN) today announced the Company has received a Complete...
Trevena to Present Phase 3, Open-Label Safety Study of Oliceridine at the American Society of Anesthesiologists Annual Meeting
October 12, 2018 16:01 ET
|
Trevena Inc.
CHESTERBROOK, Pa., Oct. 12, 2018 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ: TRVN) today announced a poster presentation at ANESTHESIOLOGY® 2018, the national conference for the American Society of...
Trevena Announces Oliceridine FDA Advisory Committee Meeting Outcome
October 11, 2018 17:04 ET
|
Trevena Inc.
CHESTERBROOK, Pa., Oct. 11, 2018 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ: TRVN), today announced the outcome of the meeting of the U.S. Food and Drug Administration (FDA) Anesthetic and Analgesic...